CoChat
Sign Up
Cited by 164

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The Role of Circulating MicroRNA-126 (miR-126): A Novel Biomarker for Screening Prediabetes and Newly Diagnosed Type 2 Diabetes Mellitus

Liu, Yang, Gao, Guangqiang, Yang, Chun, Zhou, Kun, Shen, Baozhong, Liang, Hongyan, Jiang, Xiaofeng·2014·International Journal of Molecular Sciences
DOI 10.3390/ijms150610567PMC PMC4100169
Open this paper in CoChat — free account

Abstract

Recent studies suggested an association of endothelial microRNA-126 (miR-126) with type 2 diabetes mellitus (T2DM). In the current study, we examined whether circulating miR-126 is associated with T2DM and pre-diabetic syndrome. The study included 82 subjects with impaired glucose tolerance (IGT), 75 subjects with impaired fasting glucose (IFG), 160 patients with newly diagnosed T2DM, and 138 healthy individuals. Quantitative polymerase chain reaction (qPCR) was used to examine serum miR-126. Serum miR-126 was significantly lower in IGT/IFG subjects and T2DM patients than in healthy controls (p < 0.05). After six months of treatment (diet control and exercise in IGT/IFG subjects, insulin plus diet control and exercise in T2DM patients), serum miR-126 increased significantly (p < 0.05). An analysis based on serum miR-126 in the sample revealed a significantly higher odds ratio (OR) for the subjects with the lowest 1/3 of serum miR-126 for T2DM (OR: 3.500, 95% confidence interval: 1.901–6.445, p < 0.05) than subjects within the highest 1/3 of serum miR-126. Such an association was still apparent after adjusting for other major risk factors. The area under the curve (AUC) for the receiver-operating characteristic (ROC) analysis was 0.792 (95% confidence interval: 0.707–0.877, p < 0.001). These results encourage the use of serum miR-126 as a biomarker for pre-diabetes and diabetes mellitus, as well as therapeutic response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms150610567

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Circulating miR-126 levels in the control, IGT/IFG, and new-T2DM patients. Data as shown as median (interquartile range). p < 0.001 compared to controls. Abbreviations: new-T2DM, newly diagnosed type 2 diabetes mellitus.
Figure 1 Circulating miR-126 levels in the control, IGT/IFG, and new-T2DM patients. Data as shown as median (interquartile range). p < 0.001 compared to controls. Abbreviations: new-T2DM, newly diagnosed type 2 diabetes mellitus.CC BY · PubMed Central
Figure 2 Changes in miR-126 levels after six months of treatment. Circulating miR-126 levels in IGT/IFG, new-T2DM patients before and after treatment. Data are shown as median (interquartile range).
Figure 2 Changes in miR-126 levels after six months of treatment. Circulating miR-126 levels in IGT/IFG, new-T2DM patients before and after treatment. Data are shown as median (interquartile range).CC BY · PubMed Central
Figure 3 ROC curves and corresponding AUCs for new-T2DM. The AUC in an established conventional model was 0.826 (95% CI, 0.756–0.897). After circulating miR-126 levels were introduced, the AUC was 0.893 (95% CI, 0.838–0.947). Abbreviations: AUC, area under the curve; CI, confidence interval; ROC, receiver operating characteristic.
Figure 3 ROC curves and corresponding AUCs for new-T2DM. The AUC in an established conventional model was 0.826 (95% CI, 0.756–0.897). After circulating miR-126 levels were introduced, the AUC was 0.893 (95% CI, 0.838–0.947). Abbreviations: AUC, area under the curve; CI, confidence interval; ROC, receiver operating characteristic.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 28

  1. Ambros, 2001, MicroRNAs: Tiny regulators with great potential, Cell, 107, 823, 10.1016/S0092-8674(01)00616-X · DOI
  2. Bartel, 2009, MicroRNAs: Target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002 · DOI · Paper page
  3. Bartel, 2004, MicroRNAs: Genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  4. Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc. Natl. Acad. Sci. USA, 105, 10513, 10.1073/pnas.0804549105 · DOI · Paper page
  5. Zubakov, 2010, MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation, Int. J. Leg. Med., 124, 217, 10.1007/s00414-009-0402-3 · DOI
  6. Park, 2009, Salivary microRNA: Discovery, characterization, and clinical utility for oral cancer detection, Clin. Cancer, 15, 5473, 10.1158/1078-0432.CCR-09-0736 · DOI
  7. Jeyaseelan, 2008, MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion, Stroke, 39, 959, 10.1161/STROKEAHA.107.500736 · DOI
  8. Taylor, 2008, MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer, Gynecol. Oncol., 110, 13, 10.1016/j.ygyno.2008.04.033 · DOI
  9. Tanaka, 2009, Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients, PLoS One, 4, e5532, 10.1371/journal.pone.0005532 · DOI
  10. Laterza, 2009, Plasma microRNAs as sensitive and specific biomarkers of tissue injury, Clin. Chem., 55, 1977, 10.1373/clinchem.2009.131797 · DOI
  11. Ji, 2009, Plasma miR-208 as a biomarker of myocardial injury, Clin. Chem., 55, 1944, 10.1373/clinchem.2009.125310 · DOI
  12. Wang, 2010, Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans, Eur. Heart J., 31, 659, 10.1093/eurheartj/ehq013 · DOI
  13. Fichtlscherer, 2010, Circulating microRNAs in patients with coronary artery disease, Circ. Res., 107, 677, 10.1161/CIRCRESAHA.109.215566 · DOI
  14. Tijsen, 2010, MiR423-5p as a circulating biomarker for heart failure, Circ. Res., 106, 1035, 10.1161/CIRCRESAHA.110.218297 · DOI
  15. Igaz, 2014, Potential relevance of microRNAs in the diagnostics of inflammatory bowel diseases, Orv. Hetil., 155, 487, 10.1556/OH.2014.29864 · DOI
  16. Küçükali, C.I., Kürtüncü, M., Coban, A., Cebi, M., and Tüzün, E. (2014). Epigenetics of multiple sclerosis: An updated review. Neuromol. Med., in press. · DOI
  17. Nathan, 1993, Long-term complications of diabetes mellitus, N. Engl. J. Med., 328, 1676, 10.1056/NEJM199306103282306 · DOI
  18. Frankel, 2008, Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: The Framingham offspring study, Circulation, 118, 2533, 10.1161/CIRCULATIONAHA.108.792986 · DOI
  19. 2010, Endothelial dysfunction, infiammation, and apoptosis in diabetes mellitus, Mediat. Inflamm., 2010, 792393
  20. Zampetaki, 2010, Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes, Circ. Res., 107, 810, 10.1161/CIRCRESAHA.110.226357 · DOI · Paper page
  21. Fish, 2008, miR-126 regulates angiogenic signaling and vascular integrity, Dev. Cell, 15, 272, 10.1016/j.devcel.2008.07.008 · DOI · Paper page
  22. Wang, 2008, The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis, Dev. Cell, 15, 261, 10.1016/j.devcel.2008.07.002 · DOI · Paper page
  23. Zernecke, 2009, Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection, Sci. Signal., 2, ra81, 10.1126/scisignal.2000610 · DOI
  24. Fichtlscherer, 2011, Circulating micrornas: Biomarkers or mediators of cardiovascular diseases?, Arterioscler. Thromb. Vasc. Biol., 31, 2383, 10.1161/ATVBAHA.111.226696 · DOI
  25. Asaga, 2011, Hoon1 direct serum assay for microRNA-21 concentrations in early and advanced breast cancer, Clin. Chem., 57, 84, 10.1373/clinchem.2010.151845 · DOI
  26. Murata, 2013, Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis, PLoS One, 8, e69118, 10.1371/journal.pone.0069118 · DOI
  27. Gilad, 2008, Serum microRNAs are promising novel biomarkers, PLoS One, 3, e3148, 10.1371/journal.pone.0003148 · DOI
  28. Wang, 2012, Expression of microRNAs in the urine of patients with bladder cancer, Clin. Genitourin. Cancer, 10, 106, 10.1016/j.clgc.2012.01.001 · DOI

Cited by

Sorted by citations

See all 164

Metadata

Authors
Liu, Y., Gao, G., Yang, C., Zhou, K., Shen, B., Liang, H., & Jiang, X.
Affiliations
  • Department of Clinical Biochemistry Laboratory, the 4th Affiliated Hospital of Harbin Medical University, #37 Yiyuan Street, Nangang District, Harbin 150001, China
  • Heilongjiang Province Key Laboratory of Molecular Image, Harbin 150001, China
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2014-06-12
Volume
15
Issue
6
Pages
10567-10577
ISSN
1422-0067
DOI
10.3390/ijms150610567
PMC
PMC4100169
Cited by
164
References
3
Language
en
Licence
creativecommons.org/licenses/by/3.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review